The DOI matches its Crossref record; 259 of the 259 references it cites were found in a registry or an index.
RNAi therapeutic and its innovative biotechnological evolution
Abstract
Recently, United States Food and Drug Administration (FDA) and European Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic, ONPATTRO™ (Patisiran), for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first RNAi therapeutic all over the world, as well as the first FDA-approved treatment for this indication. As a milestone event in RNAi pharmaceutical industry, it means, for the first time, people have broken through all development processes for RNAi drugs from research to clinic. With this achievement, RNAi approval may soar in the coming years. In this paper, we introduce the basic information of ONPATTRO and the properties of RNAi and nucleic acid therapeutics, update the clinical and preclinical development activities, review its complicated development history, summarize the key technologies of RNAi at early stage, and discuss the latest advances in delivery and modification technologies. It provides a comprehensive view and biotechnological insights of RNAi therapy for the broader audiences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207247 · Cited by 211
RetractedAdaptive Amphiphilic Dendrimer‐Based Nanoassemblies as Robust and Versatile siRNA Delivery Systems
Liu, X., Zhou, J., Yu, T., Chen, C., Cheng, Q., Sengupta, K., Huang, Y., Li, H., Liu, C., Wang, Y., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201406764 · Cited by 206
Self-citationRetractedPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi
Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., & Tuschl, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00908-x · Cited by 1,459
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.73 · Cited by 1,169
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
siRNAs: applications in functional genomics and potential as therapeutics
Dorsett, Y., & Tuschl, T. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1345 · Cited by 909
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Small dsRNAs induce transcriptional activation in human cells
Li, L.-C., Okino, S. T., Zhao, H., Pookot, D., Place, R. F., Urakami, S., Enokida, H., & Dahiya, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607015103 · Cited by 769
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Wilson, D. S., Dalmasso, G., Wang, L., Sitaraman, S. V., Merlin, D., & Murthy, N. (2010) · Nature Materials · doi:10.1038/nmat2859 · Cited by 747
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
Czauderna, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg393 · Cited by 623
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 609
Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma
Jensen, S. A., Day, E. S., Ko, C. H., Hurley, L. A., Luciano, J. P., Kouri, F. M., Merkel, T. J., Luthi, A. J., Patel, P. C., Cutler, J. I., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006839 · Cited by 592
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
Dahlman, J. E., Barnes, C., Khan, O. F., Thiriot, A., Jhunjunwala, S., Shaw, T. E., Xing, Y., Sager, H. B., Sahay, G., Speciner, L., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.84 · Cited by 592
Therapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
Wooddell, C. I., Yuen, M.-F., Chan, H. L.-Y., Gish, R. G., Locarnini, S. A., Chavez, D., Ferrari, C., Given, B. D., Hamilton, J., Kanner, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0241 · Cited by 490
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488
The asialoglycoprotein receptor: a model for endocytic transport receptors
Spiess, M. (1990) · Biochemistry · doi:10.1021/bi00495a001 · Cited by 485
Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways
Schwarz, D. S., Hutvágner, G., Haley, B., & Zamore, P. D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00651-2 · Cited by 471
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Robbins, M., Judge, A., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 449
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Zhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T. G., & Zhong, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.077 · Cited by 440
Woodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., & Mark Saltzman, W. (2009) · Nature Materials · doi:10.1038/nmat2444 · Cited by 438
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Guo, S., Huang, Y., Jiang, Q., Sun, Y., Deng, L., Liang, Z., Du, Q., Xing, J., Zhao, Y., Wang, P. C., et al. (2010) · ACS Nano · doi:10.1021/nn101638u · Cited by 401
Self-citationConjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells
Muratovska, A., & Eccles, M. R. (2004) · FEBS Letters · doi:10.1016/s0014-5793(03)01505-9 · Cited by 390
DiGiusto, D. L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P., Stinson, S., Kalos, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000931 · Cited by 374
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Pasi, K. J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T., Bevan, D., Austin, S., Hay, C. R., Hegemann, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616569 · Cited by 367
Schwartz, A. L., Fridovich, S. E., & Lodish, H. F. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34710-0 · Cited by 364
Advancement of the emerging field of RNA nanotechnology
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol
Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., & Yokota, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.14 · Cited by 312
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302641 · Cited by 307
Howard, K. A., Paludan, S. R., Behlke, M. A., Besenbacher, F., Deleuran, B., & Kjems, J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.220 · Cited by 299
Aleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Röder, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2428 · Cited by 293
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Self-citationRNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Han, H. D., Mangala, L. S., Lee, J. W., Shahzad, M. M. K., Kim, H. S., Shen, D., Nam, E. J., Mora, E. M., Stone, R. L., Lu, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0005 · Cited by 282
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279
Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., & Corey, D. R. (2012) · Cell · doi:10.1016/j.cell.2012.08.002 · Cited by 278
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
Shu, D., Li, H., Shu, Y., Xiong, G., Carson, W. E., Haque, F., Xu, R., & Guo, P. (2015) · ACS Nano · doi:10.1021/acsnano.5b02471 · Cited by 270
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.273 · Cited by 265
GAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 262
Specific inhibition of bcr-abl gene expression by small interfering RNA
Scherr, M., Battmer, K., Winkler, T., Heidenreich, O., Ganser, A., & Eder, M. (2003) · Blood · doi:10.1182/blood-2002-06-1685 · Cited by 259
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259
Single-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Sun, T.-M., Du, J.-Z., Yan, L.-F., Mao, H.-Q., & Wang, J. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.07.036 · Cited by 248
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H.-X., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 248
DEVINCENZO, J., CEHELSKY, J., ALVAREZ, R., ELBASHIR, S., HARBORTH, J., TOUDJARSKA, I., NECHEV, L., MURUGAIAH, V, VLIET, A., & VAISHNAW, A. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.11.009 · Cited by 247
Li, M.-J., Kim, J., Li, S., Zaia, J., Yee, J.-K., Anderson, J., Akkina, R., & Rossi, J. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.524 · Cited by 241
Tumor Targeting via Integrin Ligands
Marelli, U. K., Rechenmacher, F., Sobahi, T. R. A., Mas-Moruno, C., & Kessler, H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00222 · Cited by 236
Kumar, V., Qin, J., Jiang, Y., Duncan, R. G., Brigham, B., Fishman, S., Nair, J. K., Akinc, A., Barros, S. A., & Kasperkovitz, P. V. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.61 · Cited by 222
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
Delivery systems for siRNA drug development in cancer therapy
Xu, C.-F., & Wang, J. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.08.011 · Cited by 219
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Zimmermann, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B. R., Hutabarat, R., Nochur, S., Vaishnaw, A., & Gollob, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.019 · Cited by 216
Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1362 · Cited by 213
Dong, Y., Yu, T., Ding, L., Laurini, E., Huang, Y., Zhang, M., Weng, Y., Lin, S., Chen, P., Marson, D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10021 · Cited by 213
Self-citationThe human RNA kinase hClp1 is active on 3′ transfer RNA exons and short interfering RNAs
Weitzer, S., & Martinez, J. (2007) · Nature · doi:10.1038/nature05777 · Cited by 211
Patil, M. L., Zhang, M., & Minko, T. (2011) · ACS Nano · doi:10.1021/nn102711d · Cited by 210
RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
Zamora, M. R., Budev, M., Rolfe, M., Gottlieb, J., Humar, A., DeVincenzo, J., Vaishnaw, A., Cehelsky, J., Albert, G., Nochur, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201003-0422oc · Cited by 210
Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B. R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R. P., Erbe, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Senzer, N., Barve, M., Kuhn, J., Melnyk, A., Beitsch, P., Lazar, M., Lifshitz, S., Magee, M., Oh, J., Mill, S. W., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.269 · Cited by 198
Functional peptides for siRNA delivery
Tai, W., & Gao, X. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.004 · Cited by 197
Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins
Goodman, S. L., Hölzemann, G., Sulyok, G. A. G., & Kessler, H. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0102598 · Cited by 196
RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Kaiser, P. K., Symons, R. C. A., Shah, S. M., Quinlan, E. J., Tabandeh, H., Do, D. V., Reisen, G., Lockridge, J. A., Short, B., Guerciolini, R., et al. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.02.006 · Cited by 195
Kraft, C. S., Hewlett, A. L., Koepsell, S., Winkler, A. M., Kratochvil, C. J., Larson, L., Varkey, J. B., Mehta, A. K., Lyon, G. M., Friedman-Moraco, R. J., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ334 · Cited by 195
Inotersen: First Global Approval
Keam, S. J. (2018) · Drugs · doi:10.1007/s40265-018-0968-5 · Cited by 188
Kaneshiro, T. L., & Lu, Z.-R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.026 · Cited by 186
Rajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung
Günther, M., Lipka, J., Malek, A., Gutsch, D., Kreyling, W., & Aigner, A. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.007 · Cited by 180
Adams, D., Suhr, O. B., Dyck, P. J., Litchy, W. J., Leahy, R. G., Chen, J., Gollob, J., & Coelho, T. (2017) · BMC Neurology · doi:10.1186/s12883-017-0948-5 · Cited by 178
Gottlieb, J., Zamora, M. R., Hodges, T., Musk, A. W., Sommerwerk, U., Dilling, D., Arcasoy, S., DeVincenzo, J., Karsten, V., Shah, S., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.08.012 · Cited by 169
Hobo, W. A., Maas, F., Adisty, N., de Witte, T., Schaap, N. P., van der Voort, R., & Dolstra, H. (2010) · Blood · doi:10.1182/blood-2010-04-278739 · Cited by 167
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001997 · Cited by 165
Zhou, J., Neff, C. P., Liu, X., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Aboellail, T., Huang, Y., Du, Q., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.207 · Cited by 161
Self-citationTherapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
Nishimura, M., Jung, E.-J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., Han, H. D., Ivan, C., Rossi, S., Zhang, X., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0159 · Cited by 160
Gaus, H. J., Gupta, R., Chappell, A. E., Østergaard, M. E., Swayze, E. E., & Seth, P. P. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1260 · Cited by 160
saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription
Portnoy, V., Lin, S. H. S., Li, K. H., Burlingame, A. L., Hu, Z.-H., Li, H., & Li, L. (2016) · Cell Research · doi:10.1038/cr.2016.22 · Cited by 154
Liu, X., Rocchi, P., Qu, F., Zheng, S., Liang, Z., Gleave, M. E., Iovanna, J., & Peng, L. (2009) · ChemMedChem · doi:10.1002/cmdc.200900076 · Cited by 148
Parmar, R. G., Willoughby, J. L. S., Liu, J., Foster, D. J., Brigham, B., Theile, C. S., Charissé, K., Akinc, A., Guidry, E. N., Pei, Y., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201600130 · Cited by 146
Liu, Y., Zhu, Y., Mao, C., Dou, S., Shen, S., Tan, Z., & Wang, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.001 · Cited by 138
mRNA therapeutics deliver a hopeful message
Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 133
Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.36 · Cited by 128
Steirer, L. M., Park, E. I., Townsend, R. R., & Baenziger, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808689200 · Cited by 128
Efficient delivery of siRNA using dendritic poly(l-lysine) for loss-of-function analysis
Inoue, Y., Kurihara, R., Tsuchida, A., Hasegawa, M., Nagashima, T., Mori, T., Niidome, T., Katayama, Y., & Okitsu, O. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.022 · Cited by 126
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
Garba, A. O., & Mousa, S. A. (2010) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s4878 · Cited by 126
Cui, D., Zhang, C., Liu, B., Shu, Y., Du, T., Shu, D., Wang, K., Dai, F., Liu, Y., Li, C., et al. (2015) · Scientific Reports · doi:10.1038/srep10726 · Cited by 126
Ganesh, S., Shui, X., Craig, K. P., Park, J., Wang, W., Brown, B. D., & Abrams, M. T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.005 · Cited by 126
MicroRNAs as targets for antisense-based therapeutics
Stenvang, J., & Kauppinen, S. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.59 · Cited by 125
Mao, C., Du, J., Sun, T., Yao, Y., Zhang, P., Song, E., & Wang, J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.006 · Cited by 123
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
Gary, D. J., Lee, H., Sharma, R., Lee, J., Kim, Y.-W., Cui, Z., Jia, D., Bowman, V. D., Chipman, P. R., Wan, L., et al. (2011) · ACS Nano · doi:10.1021/nn102540y · Cited by 120
Ofek, P., Fischer, W., Calderón, M., Haag, R., & Satchi‐Fainaro, R. (2010) · The FASEB Journal · doi:10.1096/fj.09-149641 · Cited by 119
In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma
Martínez, T., González, M. V., Roehl, I., Wright, N., Pañeda, C., & Jiménez, A. I. (2013) · Molecular Therapy · doi:10.1038/mt.2013.216 · Cited by 116
Merkel, O. M., Mintzer, M. A., Librizzi, D., Samsonova, O. V., Dicke, T., Sproat, B. S., Garn, H., Barth, P. J., Simanek, E. E., & Kissel, T. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100101s · Cited by 114
Benitez-del-Castillo, J. M., Moreno‐Montañés, J., Jiménez-Alfaro, I., Muñoz-Negrete, F. J., Turman, K., Palumaa, K., Sádaba, B., González, M. V., Ruz, V., Vargas, B., et al. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20303 · Cited by 110
Guo, S., Huang, Y., Wei, T., Zhang, W., Wang, W., Lin, D., Zhang, X., Kumar, A., Du, Q., Xing, J., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.052 · Cited by 109
Self-citationRoh, Y. H., Deng, J. Z., Dreaden, E. C., Park, J. H., Yun, D. S., Shopsowitz, K. E., & Hammond, P. T. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508978 · Cited by 107
Wong, S. C., Klein, J. J., Hamilton, H., Chu, Q., Frey, C. L., Trubetskoy, V. S., Hegge, J., Wakefield, D. H., Rozema, D. B., & Lewis, D. L. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0389 · Cited by 101
Prakash, T. P., Lima, W. F., Murray, H. M., Li, W., Kinberger, G. A., Chappell, A. E., Gaus, H. J., Seth, P. P., Bhat, B., Crooke, S. T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv162 · Cited by 99
Kang, M. R., Yang, G., Place, R. F., Charissé, K., Epstein-Barash, H., Manoharan, M., & Li, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1871 · Cited by 99
Ghisoli, M. L., Barve, M. A., Mennel, R. G., Lenarsky, C., Horvath, S., Wallraven, G., Pappen, B. O., Whiting, S. H., Rao, D., Senzer, N. N., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.86 · Cited by 98
Walker, J. E., Chen, R. X., McGee, J., Nacey, C., Pollard, R. B., Abedi, M., Bauer, G., Nolta, J. A., & Anderson, J. S. (2012) · Journal of Virology · doi:10.1128/jvi.06300-11 · Cited by 97
RNAi Therapeutic Platforms for Lung Diseases
Fujita, Y., Takeshita, F., Kuwano, K., & Ochiya, T. (2013) · Pharmaceuticals · doi:10.3390/ph6020223 · Cited by 97
Tivanisiran, a novel siRNA for the treatment of dry eye disease
Moreno‐Montañés, J., Bleau, A., & Jiménez, A. I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1457647 · Cited by 97
Oh, J., Barve, M. A., Matthews, C. M., Koon, E. C., Heffernan, T. P., Fine, B. A., Grosen, E. A., Bergman, M. K., Fleming, E. L., DeMars, L. R., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.09.018 · Cited by 96
Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy
MacDiarmid, J. A., & Brahmbhatt, H. N. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.04.008 · Cited by 94
Solano, E. C. R., Kornbrust, D. J., Beaudry, A. A., Foy, J. W.-D., Schneider, D. J., & Thompson, J. D. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0489 · Cited by 91
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Janas, M. M., Harbison, C. E., Perry, V. K., Carito, B. A., Sutherland, J. E., Vaishnaw, A. K., Keirstead, N. D., & Warner, G. L. (2018) · Toxicologic Pathology · doi:10.1177/0192623318792537 · Cited by 91
Design, preparation and application of nucleic acid delivery carriers
Yang, J., Liu, H., & Zhang, X. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.11.004 · Cited by 89
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
Janas, M. M., Zlatev, I., Liu, J., Jiang, Y., Barros, S. A., Sutherland, J. E., Davis, W. P., Liu, J., Brown, C. R., Liu, X., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz140 · Cited by 88
Chitosan/siRNA Nanoparticles Biofunctionalize Nerve Implants and Enable Neurite Outgrowth
Mittnacht, U., Hartmann, H., Hein, S., Oliveira, H., Dong, M., Pêgo, A. P., Kjems, J., Howard, K. A., & Schlosshauer, B. (2010) · Nano Letters · doi:10.1021/nl1016909 · Cited by 87
Tao, J., Zhang, R., Singh, S., Poddar, M., Xu, E., Oertel, M., Chen, X., Ganesh, S., Abrams, M. T., & Monga, S. P. (2016) · Hepatology · doi:10.1002/hep.28975 · Cited by 86
Thompson, J. D., Kornbrust, D. J., Foy, J. W.-D., Solano, E. C. R., Schneider, D. J., Feinstein, E., Molitoris, B. A., & Erlich, S. S. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0371 · Cited by 85
Guo, S., Huang, Y., Zhang, W., Wang, W., Wei, T., Lin, D., Xing, J., Deng, L., Du, Q., Liang, Z., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.034 · Cited by 84
Self-citationShu, D., Khisamutdinov, E. F., Zhang, L., & Guo, P. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt885 · Cited by 83
Developing Small Activating RNA As a Therapeutic: Current Challenges and Promises
Kwok, A., Raulf, N., & Habib, N. (2019) · Therapeutic Delivery · doi:10.4155/tde-2018-0061 · Cited by 83
Wolstein, O., Boyd, M. P., Millington, M., Impey, H., Boyer, J., Howe, A., Delebecque, F., Cornetta, K. G., Rothe, M., Baum, C., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.11 · Cited by 82
Self-citationDutta, C., Avitahl-Curtis, N., Pursell, N., Larsson Cohen, M., Holmes, B., Diwanji, R., Zhou, W., Apponi, L., Koser, M., Ying, B., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.4 · Cited by 81
Huang, D., Zhao, D., Wang, X., Li, C., Yang, T., Du, L., Wei, Z., Cheng, Q., Cao, H., Liang, Z., et al. (2018) · Theranostics · doi:10.7150/thno.23438 · Cited by 81
Self-citationThe epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis
Shei, R., Lever, J. E. P., Kaza, N., & Rowe, S. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.09.007 · Cited by 81
A ribonucleoprotein octamer for targeted siRNA delivery
Tai, W., Li, J., Corey, E., & Gao, X. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0214-1 · Cited by 80
Zhang, T., Huang, Y., Ma, X., Gong, N., Liu, X., Liu, L., Ye, X., Hu, B., Li, C., Tian, J., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02553 · Cited by 80
Self-citationXu, C., Haque, F., Jasinski, D. L., Binzel, D. W., Shu, D., & Guo, P. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.043 · Cited by 79
Zhou, J., Wu, Y., Wang, C., Cheng, Q., Han, S., Wang, X., Zhang, J., Deng, L., Zhao, D., Du, L., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02915 · Cited by 78
Self-citationMoreno-Montañés, J., Sádaba, B., Ruz, V., Gómez-Guiu, A., Zarranz, J., González, M. V., Pañeda, C., & Jimenez, A. I. (2014) · Molecular Therapy · doi:10.1038/mt.2013.217 · Cited by 76
Javanbakht, H., Mueller, H., Walther, J., Zhou, X., Lopez, A., Pattupara, T., Blaising, J., Pedersen, L., Albæk, N., Jackerott, M., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.005 · Cited by 76
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
Yang, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567326 · Cited by 76
Liao, Z., Ho, Y., Chen, H., Peng, S., Hsiao, C., & Sung, H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.086 · Cited by 75
Zheng, S., Wang, X., Weng, Y., Jin, X., Ji, J.-L., Guo, L.-X., Hu, B., Liu, N., Cheng, Q., Zhang, J., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.08.003 · Cited by 75
Self-citationMolecular basis of primary hyperoxaluria: clues to innovative treatments
Dindo, M., Conter, C., Oppici, E., Ceccarelli, V., Marinucci, L., & Cellini, B. (2018) · Urolithiasis · doi:10.1007/s00240-018-1089-z · Cited by 75
Burke, B. P., Levin, B. R., Zhang, J., Sahakyan, A., Boyer, J., Carroll, M. V., Colón, J. C., Keech, N., Rezek, V. K., Bristol, G. C., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.10 · Cited by 72
Self-citationShmushkovich, T., Monopoli, K. R., Homsy, D., Leyfer, D., Betancur-Boissel, M., Khvorova, A., & Wolfson, A. D. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky745 · Cited by 72
Koldehoff, M., Steckel, N. K., Beelen, D. W., & Elmaagacli, A. H. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0125-z · Cited by 69
Kano, A., Moriyama, K., Yamano, T., Nakamura, I., Shimada, N., & Maruyama, A. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.007 · Cited by 69
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
Dannull, J., Haley, N. R., Archer, G. E., Nair, S. K., Boczkowski, D., Harper, M., de Rosa, N., Pickett, N., Mosca, P. J., Burchette, J. L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67544 · Cited by 69
Turner, A. M., Stolk, J., Bals, R., Lickliter, J. D., Hamilton, J., Christianson, D. R., Given, B. D., Burdon, J. G., Loomba, R., Stoller, J. K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.012 · Cited by 67
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line
Dowling, J. J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.180 · Cited by 67
Lin, D., Huang, Y., Jiang, Q., Zhang, W., Yue, X., Guo, S., Xiao, P., Du, Q., Xing, J., Deng, L., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.089 · Cited by 65
Self-citationDirect Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
Ganesh, S., Koser, M. L., Cyr, W. A., Chopda, G. R., Tao, J., Shui, X., Ying, B., Chen, D., Pandya, P., Chipumuro, E., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0309 · Cited by 64
Yamakawa, T., Ohigashi, H., Hashimoto, D., Hayase, E., Takahashi, S., Miyazaki, M., Minomi, K., Onozawa, M., Niitsu, Y., & Teshima, T. (2018) · Blood · doi:10.1182/blood-2017-04-779934 · Cited by 63
Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model
Suhy, D. A., Kao, S.-C., Mao, T. K., Whiteley, L. O., Denise, H., Souberbielle, B. E., Burdick, A. D., Hayes, K., Wright, J. F., Lavender, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.119 · Cited by 62
VEGF inhibitors for the treatment of neovascular age-related macular degeneration
Barakat, M., & Kaiser, P. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902855316 · Cited by 62
Targeted siRNA delivery using aptamer‐siRNA chimeras and aptamer‐conjugated nanoparticles
Sivakumar, P., Kim, S., Kang, H. C., & Shim, M. S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1543 · Cited by 60
Recent preclinical and clinical advances in oligonucleotide conjugates
Craig, K. P., Abrams, M. T., & Amiji, M. M. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1473375 · Cited by 57
New Frontiers in Lp(a)-Targeted Therapies
Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 57
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Ghisoli, M. L., Barve, M. A., Schneider, R., Mennel, R. G., Lenarsky, C., Wallraven, G., Pappen, B. O., LaNoue, J., Kumar, P., Nemunaitis, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.43 · Cited by 56
Prakash, T. P., Kinberger, G. A., Murray, H. M., Chappell, A. E., Riney, S., Graham, M. J., Lima, W. F., Swayze, E. E., & Seth, P. P. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.063 · Cited by 55
Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown
Bäumer, N., Appel, N., Terheyden, L., Buchholz, F., Rössig, C., Müller‐Tidow, C., Berdel, W. E., & Bäumer, S. (2015) · Nature Protocols · doi:10.1038/nprot.2015.137 · Cited by 54
Zhou, J., Zhao, Y., Simonenko, V., Xu, J. J., Liu, K., Wang, D., Shi, J., Zhong, T., Zhang, L., Zeng, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20869 · Cited by 54
Huang, Y., Lin, D., Jiang, Q., Zhang, W., Guo, S., Xiao, P., Zheng, S., Wang, X., Chen, H., Zhang, H., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.052 · Cited by 53
Self-citation
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Self-citationAdvances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Self-citationThe growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475
A Hitchhiker’s Guide to Click-Chemistry with Nucleic Acids
Fantoni, N. Z., El-Sagheer, A. H., & Brown, T. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00928 · Cited by 462
Metadata
- Authors
- Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 37
- Issue
- 5
- Pages
- 801-825
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2942046145
- Cited by
- 286
- References
- 259
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.